Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function
Main finding · New-onset proteinuriaResult — go to the resultHazard ratio 1.64 95% CI 1.15–2.33Authors' conclusion
Empagliflozin was associated with a lower risk of new-onset proteinuria compared with dapagliflozin. These findings underscore the importance of individualised SGLT2 inhibitor selection but require confirmation in randomised controlled trials.
Study context
- Population
- Patients with T2D (HbA1c ≥ 6.5%, antidiabetic drugs and/or T2D codes) and preserved kidney function (eGFR ≥ 60 mL/min/1.73 m², urinary protein < 1+, no history of CKD), April 2014–March 2023; mean age 67.5 ± 10.3 years, 60% men
- Exposure
- Empagliflozin vs dapagliflozin vs canagliflozin
- Outcome
- New-onset proteinuria
- Follow-up
- Median 522 [263-925] days
Methodological detailsobservational cohort study, inverse probability of treatment weighting, inverse probability of censoring weighting, health checkup and claims databases
- Observational cohort study
- Inverse probability of treatment weighting
- Inverse probability of censoring weighting
- Health checkup and claims databases
Main finding
As reported in the abstract
Hazard ratio
1.64
95% CI 1.15–2.33
Events by group
Empagliflozin
43
events
Dapagliflozin
66
events
Canagliflozin
48
events
Dapagliflozinvs Empagliflozin
HR 1.64 (95% CI 1.15–2.33)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| New-onset proteinuria, menDapagliflozinvs Empagliflozin | 2.34 (1.53–3.58) | P for heterogeneity < 0.01 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function. Diabetes Obes Metab. Published 9 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →